Government Trades

Viatris Inc (VTRS) Government Trades - Latest Congressional Stock Transactions

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

top performing (VTRS) trades

Robert Bresnahan headshot
Robert Bresnahan
House (R-PA)
31.10%
Daniel Goldman headshot
Daniel Goldman
House (D-NY)
-13.90%

Recent Viatris (VTRS) Trades by Congress Members

See the most up-to-date Viatris trades disclosed by US lawmakers, including purchase and sale amounts, transaction dates, and reporting details. View the most recent Viatris trades made by congress members.

Robert BresnahanHouse (R-PA)
$1K - $15KstockSaleMay 08, 2025Apr 08, 2025
House
$1K - $15KstockSale (Partial)Apr 07, 2025Mar 31, 2025
House
Robert BresnahanHouse (R-PA)
$1K - $15KstockPurchaseMar 27, 2025Feb 25, 2025
House
Daniel GoldmanHouse (D-NY)
$1K - $15KstockSale (Partial)May 19, 2023Apr 10, 2023
House
Daniel GoldmanHouse (D-NY)
$1K - $15KstockSale (Partial)Apr 17, 2023Mar 06, 2023
House
Daniel GoldmanHouse (D-NY)
$1K - $15KstockPurchaseFeb 24, 2023Jan 31, 2023
House